B+
Bull case
0%
Probability
Target price
$255.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
LGND
LigandDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that Q1 preserved the bigger thesis despite the headline miss: royalty revenue still grew 56% year over year, Filspari received full FDA approval in FSGS and was called Ligand's largest royalty contributor, cash and investments rose to $779.4 million at March 31, 2026, and management reaffirmed the previously raised 2026 guidance tied to XOMA [#8-K-2026-05-07].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.8.
What can break
Ligand remains dependent on partners for regulatory approvals, launch execution, sales conversion, and milestone timing across the royalty portfolio.
Momentum
35
Value
60
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $228.00 · Bull $255.00 · Bear $180.00Analysis 2026-05-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $352.40
Why
Momentum35 · Δ7d -21.6
Value60 · Δ7d -0.0
Sentiment34 · Δ7d +1.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +1.8.
Contradictions & invalidation
- • Ligand remains dependent on partners for regulatory approvals, launch execution, sales conversion, and milestone timing across the royalty portfolio.
- • Non-cash fair-value movements, including the Pelthos-related mark in Q1, can obscure underlying operating progress and create earnings volatility [#8-K-2026-05-07] [#10-Q-2026-05-08].
- • The bear case is that the stock still depends heavily on partner-controlled assets, quarter-to-quarter reported results can be distorted by Captisol order timing and investment marks, and the most visible 2026 upside now leans on a pending acquisition rather than purely organic execution.
Catalyst clock
2026-05-15
Q1 earnings miss is now offset against reaffirmed full-year guidance
Lead driver: Sentiment · See AI snapshot
Momentum
35
9% active weight
Current posture
7d trendSoftening
Δ7d
-21.6
Δ21d
-19.9
Value
60
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.2
Sentiment
34
62% active weight
Current posture
7d trendImproving
Δ7d
+1.8
Δ21d
+1.4
Why this grade
Composite grade D. Momentum 34.7 / Value 60.2 / Sentiment 34.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-09. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$228.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$180.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$5.82B
Beta
1.20
Shares Out
19.94M
P/E (TTM)
92.4
P/S (TTM)
15.04
P/FCF (TTM)
122.87
Rev YoY
+33.7%
EPS YoY
+813.4%
Gross Margin
+84.3%
Op Margin
+34.5%
Net Debt
-$282.03M
Current Ratio
31.18
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data